Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell): lines of therapy
4 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Localised disease | Right hemicolectomy with lymphadenectomy; adjuvant FOLFOX or CAPOX for node-positive or high-risk stage II disease, extrapolated from colon cancer. | NCCN Guidelines: Colon Cancer (appendiceal section) | 82 | |
| All comers | Peritoneal metastases, resectable | Cytoreductive surgery with HIPEC (mitomycin or oxaliplatin) in fit patients with limited disease and favourable histology, with perioperative systemic chemotherapy. | NCCN Guidelines: Colon Cancer (appendiceal section) | 82 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Unresectable or distant metastatic disease | FOLFOX or CAPOX with or without bevacizumab; FOLFIRI in second line; pembrolizumab for mismatch-repair-deficient tumours. | NCCN Guidelines: Colon Cancer (appendiceal section) | 98 | |
| All comers | Signet ring cell carcinoma with extensive peritoneal disease | Systemic chemotherapy first; cytoreduction only for exceptional responders. | NCCN Guidelines: Colon Cancer (appendiceal section) | 82 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.